【Craftsmanship in Partnership, Guardians of Health】— European-Quality Imatinib, Delivering a High-Quality Imatinib Product Series
Zhejiang Kisun Pharma, in collaboration with STADA Germany, introduces multi-strength Imatinib Mesylate Tablets (100mg/400mg). Strictly adhering to EU GMP standards, the products ensure clinical equivalence to the originator drugs, providing reliable treatment options for physicians and alleviating the financial burden for patients.
International Quality, Local Accessibility
Leveraging mature manufacturing processes and quality systems established for exports to Europe, the product portfolio includes brands such as Imatinib EG STADA. The packaging is marked with "MEDICINALE EQUIVALENTE" (European Medicinal Equivalent Identifier). Supported by the dual assurance of China-German technological integration, European patients now have access to internationally standardized anti-tumor medications manufactured by Kiusn Pharma, enhancing treatment accessibility and alleviating the therapeutic burden.
Precision Strength, Scientifically Guarded
The blue and green color-coded packaging clearly differentiates product strengths. The 100mg/400mg film-coated tablets are designed for easy oral administration. Available in pack sizes of 30, 60, or 120 tablets per box, the product is tailored to reasonably meet the course requirements of different patients. With end-to-end quality control from API to drug product, it exemplifies the combined technical expertise of both partners in the field of oncology medicines.
Zhejiang Kisun Pharma rigorously fulfills its pharmaceutical mission. In partnership with STADA, Kisun is making high-quality international medicines readily accessible, injecting solid strength into life and health.
Keywords:
Related News
Pharmacovigilance
Tel:+86-576-88113608
Email:pv@kisunpharm.net
Let's stay in touch and keep up with the company's latest updates.
